In This Article:
Tevogen (TVGN) reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1B in revenue in its launch year and a cumulative five-year estimate of between $10B and $14B. The forecast reflects the company’s drug development model. “With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,” commented Ryan Saadi, founder and CEO of Tevogen.
Protect Your Portfolio Against Market Uncertainty
-
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
-
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TVGN: